/
MARKET IS OPEN
Loading latest tickers...

Market Indices

S&P 500
$7,666.45
+0.19%
NASDAQ 100
$30,501.56
+0.31%
DOW JONES
$50,927.00
+0.04%
NASDAQ Composite
$26,871.60
+0.04%
RUSSELL 2000
$2,790.20
+0.41%
CBOE VIX
$16.39
+0.31%

Sector Heatmap

Technology+1.05%
Financials+0.11%
Healthcare-1.32%
Consumer Cycl-0.03%
Consumer Staples-0.33%
Energy+1.95%
Industrials+0.99%
Materials-0.33%
Real Estate-0.56%
Utilities+0.61%
Comm Services-0.93%

AKBA — Akebia Therapeutics, Inc.

Nasdaq

Akebia Therapeutics, Inc.

Back to Screener
$0.87
-0.05(-5.33%)
O
0.91
H
0.92
L
0.87
V
4.5M
⏱️ End-of-day dataAs of Oct 1, 2026
OverviewStatisticsFinancialsHistorical DataOptionsDividend HistoryNewsChart

Akebia Therapeutics, Inc. Statistics

Total Valuation

Market Cap$248.34M
Enterprise Value$268.47M

Important Dates

Earnings Daten/a
Ex-Dividend Daten/a

Share Statistics

Current Share Classn/a
Shares Outstanding277.11M
Shares Change (YoY)n/a
Shares Change (QoQ)n/a
Owned by Insiders (%)n/a
Owned by Institutions (%)n/a
Floatn/a

Valuation Ratios

PE Ration/a
Forward PEn/a
PS Ration/a
Forward PSn/a
PB Ratio87.10
P/TBV Ration/a
P/FCF Ration/a
P/OCF Ration/a
PEG Ration/a

Enterprise Valuation

EV / Earnings-29.65
EV / Salesn/a
EV / EBITDA-61.51
EV / EBIT-63.36
EV / FCF-12.62

Financial Position

Current Ratio1.40
Quick Ration/a
Debt / Equity13.29
Debt / EBITDA-8.34
Debt / FCF-1.71
Interest Coveragen/a

Financial Efficiency

Return on Equity (ROE)-330.74%
Return on Assets (ROA)-24.98%
Return on Invested Capital (ROIC)n/a
Return on Capital Employed (ROCE)n/a
Weighted Average Cost of Capital (WACC)n/a
Revenue Per Employeen/a
Profits Per Employee$-46,670
Employee Count194
Asset Turnovern/a
Inventory Turnovern/a

Taxes

Income Tax$126.00K
Effective Tax Raten/a

Stock Price Statistics

Beta (5Y)n/a
52-Week Price Change-67.50%
50-Day Moving Average$0.99
200-Day Moving Average$1.23
Relative Strength Index (RSI)39.08
Average Volume (20 Days)6,242,352

Short Selling Information

Short Interestn/a
Short Previous Monthn/a
Short % of Shares Outn/a
Short % of Floatn/a
Short Ratio (days to cover)n/a

Income Statement

Revenuen/a
Gross Profit$41.25M
Operating Income-$4.70M
Pretax Income-$8.93M
Net Income-$9.05M
EBITDA-$4.37M
EBIT-$4.24M
Loss Per Share$-0.03

Balance Sheet

Cash & Cash Equivalents$16.26M
Total Debt$36.40M
Net Cash-$20.13M
Net Cash Per Share$-0.07
Equity (Book Value)$2.74M
Book Value Per Share$0.01
Working Capital$6.96M

Cash Flow

Operating Cash Flow-$26.37M
Capital Expenditures-$62.00K
Depreciation & Amortizationn/a
Net Borrowingn/a
Free Cash Flow-$21.27M
FCF Per Share$-0.08

Margins

Gross Marginn/a
Operating Marginn/a
Pretax Marginn/a
Profit Marginn/a
EBITDA Marginn/a
EBIT Marginn/a
FCF Marginn/a

Dividends & Yields

Dividend Per Sharen/a
Dividend Yieldn/a
Dividend Growth (YoY)n/a
Years of Dividend Growthn/a
Payout Ration/a
Buyback Yieldn/a
Shareholder Yieldn/a
Earnings Yieldn/a
FCF Yield-8.56%

Analyst Forecast

Price Targetn/a
Price Target Differencen/a
Analyst Consensusn/a
Analyst Countn/a
Revenue Growth Forecast (3Y)n/a
EPS Growth Forecast (3Y)n/a

Fair Value

Lynch Fair Valuen/a
Lynch Upsiden/a
Graham Numbern/a
Graham Upsiden/a

Stock Splits

Last Split Daten/a
Split Typen/a
Split Ration/a

Scores

Altman Z-Scoren/a
Piotroski F-Scoren/a